desloratadine (Aerius)

12/01/2002 - "In patients suffering from allergic rhinitis, rhinomanometry showed a significant improvement in nasal congestion by desloratadine. "
06/01/2007 - "Whether regular or on-demand use of desloratadine influences its therapeutic efficacy in allergic rhinitis is unknown. "
11/01/2006 - "When administered once daily, desloratadine is effective in alleviating the morning symptoms of allergic rhinitis, including nasal congestion. "
01/01/2010 - "Efficacy of desloratadine in persistent allergic rhinitis - a GA²LEN study."
10/01/2009 - "Efficacy of desloratadine in intermittent allergic rhinitis: a GA(2)LEN study."

09/01/2008 - "CONCLUSION: In an open-label, observational study, desloratadine 5 mg once daily significantly decreased symptoms of chronic idiopathic urticaria and improved subject QoL."
03/01/2009 - "Desloratadine, a non-sedating, second-generation H(1)-receptor antagonist, is an effective and well-tolerated treatment for chronic idiopathic urticaria (CIU). "
01/01/2010 - "The aim of this investigation was to evaluate the safety, tolerability and efficacy of desloratadine 5 mg once daily in four postmarketing surveillance studies in subjects with seasonal AR (SAR) or chronic idiopathic urticaria (CIU) in real-world clinical practice settings. "
03/01/2009 - "Safety and efficacy of desloratadine in chronic idiopathic urticaria in clinical practice: an observational study of 9246 patients."
09/01/2008 - "Impact of Desloratadine on Symptoms and Quality of Life in Subjects with Chronic Idiopathic Urticaria: A Multicenter, Practice-based Study."

01/01/2001 - "Oral desloratadine 5 mg once daily for up to 4 weeks in patients with seasonal allergic rhinitis (SAR) significantly reduced nasal (including congestion) and non-nasal symptoms and improved health-related quality of life compared with placebo. "
08/05/2002 - "Early studies with desloratadine demonstrated efficacy in treating seasonal allergic rhinitis (SAR). "
03/01/2007 - "Effectiveness of desloratadine 5 mg once daily in patients with symptoms of seasonal allergic rhinitis: results of a Canadian multicenter, open-label trial."
11/01/2005 - "The effect of desloratadine on eosinophil/basophil progenitors and other inflammatory markers in seasonal allergic rhinitis: a placebo-controlled randomized study."
02/02/2005 - "Morning versus evening dosing of desloratadine in seasonal allergic rhinitis: a randomized controlled study [ISRCTN23032971]."

08/01/2009 - "In two 4-week studies, one comparing LCZ 5 mg/d with placebo and the other comparing it with desloratadine (DSL), LCZ was significantly more effective than either comparator in terms of improvement in scores for pruritus severity (P < or = 0.001 vs placebo; P < 0.004 vs DSL) and duration (P < or = 0.001 vs placebo; P = 0.009 vs DSL). "
08/01/2008 - "Three 6-week double-blind, placebo-controlled trials (n = 553) found that desloratadine significantly (p < 0.05) improved patient-reported pruritus, sleep disruption, and interference with daily activities. "
07/01/2009 - "Desloratadine was significantly more effective than placebo in preventing post-challenge ocular pruritus (P<0.001). "
01/01/2007 - "Desloratadine treatment was associated with significant improvements compared with placebo in pruritus scores and in the size of the largest wheals as early as day 1. These improvements continued through to the end of the trial. "
01/01/2002 - "Desloratadine was superior to placebo in controlling pruritus and total symptoms after the first dose, and its superiority was maintained throughout the full 6 weeks of the study. "

11/01/2002 - "To evaluate the safety and efficacy of desloratadine 5 mg in patients experiencing moderate SAR, nasal congestion, and symptoms of seasonal allergic asthma. "
01/01/2002 - "In patients with concomitant asthma and SAR, asthma symptoms are relieved and beta2-agonist medication use is decreased by desloratadine. "
02/01/2005 - "The aim of this study was to evaluate the effect of desloratadine (5 mg daily) on rescue medication use, symptoms of SAR and asthma. "
01/01/2001 - "Desloratadine was well tolerated in clinical trials and had an adverse event profile similar to that of placebo in patients with SAR (with or without asthma) or CIU."
02/01/2005 - "Desloratadine in the dosis of 5 mg daily confirmed its efficacy and safety in the treatment of patients with SAR and asthma. "